| Literature DB >> 16759054 |
Eva Herrmann1, Stefan Zeuzem, Christoph Sarrazin, Holger Hinrichsen, Yves Benhamou, Michael P Manns, Markus Reiser, Henk Reesink, José L Calleja, Xavier Forns, Gerhard G Steinmann, Gerhard Nehmiz.
Abstract
We analysed viral kinetics from a 2-day treatment with BILN 2061, a serine protease inhibitor of hepatitis C virus, in patients chronically infected with genotype 1 hepatitis C virus. The efficiency (E), describing inhibition of viral production, was above 99.45% in all patients with minor or moderate fibrosis receiving doses of 200mg and 500 mg twice daily and larger than in previous studies for interferon-based treatments. However, epsilon was slightly smaller in patients with cirrhosis given 200mg and markedly smaller in patients given 25 mg. Estimates of viral clearance and infected-cell loss support conclusions on these rates and on treatment mechanisms from previous studies on interferon-alpha-based treatments.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16759054
Source DB: PubMed Journal: Antivir Ther ISSN： 1359-6535